BRYGZU

Serial Number 98608119
730

Registration Progress

Application Filed
Jun 19, 2024
Under Examination
Nov 26, 2024
Approved for Publication
Oct 1, 2024
Published for Opposition
Oct 1, 2024
Registered

Basic Information

Serial Number
98608119
Deadline
November 26, 2025
Description
Statement of Use or 2nd Extension Due
Filing Date
June 19, 2024
Published for Opposition
October 1, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
730
Status Date
Apr 21, 2025
Application
Pending
Classes
005

Rights Holder

Eli Lilly and Company

03
Address
Lilly Corporate Center
Indianapolis, IN 46285

Ownership History

Eli Lilly and Company

Original Applicant
03
Indianapolis, IN

Eli Lilly and Company

Owner at Publication
03
Indianapolis, IN

Legal Representation

Attorney
Bruce W. Longbottom
USPTO Deadlines 1 active 1 overdue
Deadline Type Event Code Deadline Date Days Until Priority Extension Available
OPPOSITION
Notice of Publication
NPUBE Oct 31, 2024 249 days overdue Medium Until Nov 30, 2024

Application History

12 events
Date Code Type Description
Apr 21, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 21, 2025 EX1G S SOU EXTENSION 1 GRANTED
Apr 21, 2025 EXT1 S SOU EXTENSION 1 FILED
Apr 21, 2025 EEXT I SOU TEAS EXTENSION RECEIVED
Nov 26, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 1, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 1, 2024 PUBO A PUBLISHED FOR OPPOSITION
Sep 11, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 27, 2024 DOCK D ASSIGNED TO EXAMINER
Aug 27, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 19, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 19, 2024 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, hearing loss, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases

Active Deadlines

Notice of Publication
Due: Oct 31, 2024 Overdue

Classification

International Classes
005